Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Cancer Immunology Research|December 5, 2023
Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and MacrophagesMaria Cristina Manara, Cristina Manferdini, Camilla Cristalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agentsAna Teresa Amaral, Cecilia Garofalo, Roberta Frapolli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2017
Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint InhibitorsChiara Ratti, Laura Botti, Valeria Cancila, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 23, 2022
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axisMichela Pasello, Anna Maria Giudice, Camilla Cristalli, et al.
Cancer Research|December 14, 2021
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 SarcomaMarianna Carrabotta, Maria Antonella Laginestra, Giorgio Durante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicinClara Guerzoni, Valentina Fiori, Mario Terracciano, et al.
Scientific Reports|August 23, 2019
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigationsPatrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, et al.
Oncogene|February 1, 2018
Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99Haydar Çelik, Marika Sciandra, Bess Flashner, et al.
Clinical Epigenetics|May 8, 2019
Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cellsClemens Zwergel, Michael Schnekenburger, Federica Sarno, et al.
Cancers|June 24, 2022
Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative StudyEmanuela Palmerini, Laura Pazzaglia, Luca Cevolani, et al.
Pageof 8